Greenphire Appoints Senior Director of Business Development in Europe
News Oct 10, 2013
Based in London, Alex will be responsible for developing market awareness of Greenphire's solutions and will lead the company's overall business development strategy in Europe. He joins Greenphire having previously served as Global Account Manager at Phase Forward (now Oracle), where he was charged with driving worldwide sales strategies. Previous to this role, he worked for G.D. Searle prior to its acquisition by Pfizer.
"Having admired Greenphire's achievements in the clinical payment technology field, its innovative nature and dynamic management team, I am delighted to have been chosen to lead the next stage of the company's development in Europe", comments Alex Livingstone. "I am excited to join a brand where innovation is valued and the desire to change things for the better is at the core of its strategy."
Commenting on the new appointment, Greenphire CEO Sam Whitaker said, "Alex's extensive experience in the industry will be a tremendous asset to Greenphire at a time when we are developing quickly as a business. He will play a key role in capturing commercial opportunities in key markets across Europe and I am confident Alex will be a strong asset to Greenphire and our clients alike."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018